Related Experiment Videos
Sarcoma
1Memorial Sloan-Kettering Cancer Center, New York, New York 10021-6007, USA. makir@mskcc.org
The Oncologist
|August 29, 2001
Summary
New systemic therapies show promise for sarcoma treatment. Imatinib mesylate, ecteinascidin-743, and gemcitabine-based regimens offer hope for effective sarcoma treatment options.
Area of Science:
- Oncology
- Pharmacology
Background:
- Sarcomas remain challenging to treat with limited effective systemic therapies.
- The development of novel targeted agents is crucial for improving patient outcomes.
Purpose of the Study:
- To review innovative systemic therapies for sarcomas presented at ASCO 2001.
- To highlight agents showing significant activity in preclinical and clinical studies.
Main Methods:
- Review of data presented at ASCO 2001.
- Focus on systemic agents including imatinib mesylate, ecteinascidin-743, and gemcitabine.
Main Results:
- Imatinib mesylate (STI571, Gleevec) demonstrated activity in chronic myelogenous leukemia and gastrointestinal stromal tumors.
- Ecteinascidin-743 (ET-743) showed activity in a subset of soft-tissue sarcomas.
- Gemcitabine-based regimens exhibited activity against certain soft-tissue sarcomas.
Conclusions:
- The emergence of imatinib mesylate, ET-743, and gemcitabine offers new hope for effective sarcoma systemic therapy.
- These findings suggest a potential paradigm shift in sarcoma treatment strategies.